Tenaya Therapeutics (TNYA) Projected to Post Earnings on Thursday

Key Points

• Tenaya Therapeutics is expected to report Q2 2025 earnings on August 14, with analysts forecasting a loss of ($0.17) per share.
• The company's stock has a market capitalization of $109.74 million and institutional investors own approximately 90.54% of its shares.
• Analysts maintain a consensus rating of "Buy" for Tenaya Therapeutics, with price targets ranging from $5.00 to $9.00 per share.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) is expected to be releasing its Q2 2025 earnings data before the market opens on Thursday, August 14th. Analysts expect Tenaya Therapeutics to post earnings of ($0.17) per share for the quarter.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.06. On average, analysts expect Tenaya Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tenaya Therapeutics Stock Performance

TNYA traded up $0.01 on Friday, hitting $0.67. The company had a trading volume of 1,244,207 shares, compared to its average volume of 2,309,370. The stock has a fifty day moving average price of $0.67 and a 200-day moving average price of $0.67. Tenaya Therapeutics has a 12-month low of $0.36 and a 12-month high of $4.01. The stock has a market capitalization of $109.02 million, a price-to-earnings ratio of -0.70 and a beta of 3.01.

Institutional Investors Weigh In On Tenaya Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Comerica Bank acquired a new stake in shares of Tenaya Therapeutics during the first quarter worth about $50,000. AQR Capital Management LLC acquired a new stake in shares of Tenaya Therapeutics during the first quarter worth about $442,000. Finally, Woodline Partners LP lifted its holdings in shares of Tenaya Therapeutics by 30,563.2% during the first quarter. Woodline Partners LP now owns 5,916,167 shares of the company's stock worth $3,373,000 after purchasing an additional 5,896,873 shares during the period. Institutional investors and hedge funds own 90.54% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on TNYA. HC Wainwright reiterated a "buy" rating and issued a $5.00 target price on shares of Tenaya Therapeutics in a research note on Friday, April 25th. Wall Street Zen raised Tenaya Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday. Finally, Chardan Capital reissued a "buy" rating and issued a $9.00 price target on shares of Tenaya Therapeutics in a report on Thursday. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $6.25.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.